|
Dimitrios Iliopoulos, PhD, MBA
President & CEO, Athos Therapeutics Inc. Chairman, Attica Sciences Ltd. Los Angeles, CA USA |
Since 2024Dimitrios grew up in the city of Volos, a coastal city in Greece and homeland of the mythological hero Jason and the Argonauts. After completing his undergraduate studies in the School of Biology at the Aristotle University in Thessaloniki, Dimitrios moved in the United States to pursue his dream: “Expand his knowledge and develop new therapies for patients”. He learned to work with novel high technologies next to a giant of molecular biology, Kevin Struhl, a professor at Harvard Medical School. At the age of 31, Dimitrios was elected as an Assistant Professor at Harvard Medical School and Dana-Farber Cancer Institute in Boston. At the age of 34 he got tenured at UCLA and was elected as an Associate Professor of Medicine and Director of the UCLA Center for Systems Biomedicine, a high technology center aiming to expedite the drug discovery process. He also holds an MBA degree from UCLA Anderson School of Management, a certificate on M&A from Stanford Business School and a certificate on Artificial Intelligence from Massachusetts Institute of Technology (MIT).
He has received several national and international awards from National Institute of Digestive Diseases (NIDDK), the American Association for Cancer Research, the Sidney Kimmel Foundation and the Leona & Harry Helmsley Foundation for the identification of novel genes and development of therapeutics for patients with cancer and autoimmune diseases. He has published >130 scientific articles in top tier biomedical journals, including Cell, Cancer Cell, Nature, PNAS and Gastroenterology, having >17,000 citations and holds 9 patents.
Currently, Dr. Iliopoulos is a co-founder, President & CEO of Athos Therapeutics Inc., a biotech platform company, located in Los Angeles, that develops precision therapeutics for patients with chronic inflammatory diseases using artificial intelligence. Furthermore, he is Chairman of Attica Sciences Ltd., a pharma company in Greece, developing novel preventative and therapeutic products derived from olive oil and other Greek herbs. Also, he is the scientific director at Dyania Health, a digital health company that automates and expedites the process of matching patients with human clinical trials.
In 2019, Dimitrios Iliopoulos was a co-founder of the ARISTEiA-Institute for the Advancement of Research & Education in Arts, Sciences &Technology. Since 2024, he serves as the Vice-President of the Executive Council of the Institute.
He has received several national and international awards from National Institute of Digestive Diseases (NIDDK), the American Association for Cancer Research, the Sidney Kimmel Foundation and the Leona & Harry Helmsley Foundation for the identification of novel genes and development of therapeutics for patients with cancer and autoimmune diseases. He has published >130 scientific articles in top tier biomedical journals, including Cell, Cancer Cell, Nature, PNAS and Gastroenterology, having >17,000 citations and holds 9 patents.
Currently, Dr. Iliopoulos is a co-founder, President & CEO of Athos Therapeutics Inc., a biotech platform company, located in Los Angeles, that develops precision therapeutics for patients with chronic inflammatory diseases using artificial intelligence. Furthermore, he is Chairman of Attica Sciences Ltd., a pharma company in Greece, developing novel preventative and therapeutic products derived from olive oil and other Greek herbs. Also, he is the scientific director at Dyania Health, a digital health company that automates and expedites the process of matching patients with human clinical trials.
In 2019, Dimitrios Iliopoulos was a co-founder of the ARISTEiA-Institute for the Advancement of Research & Education in Arts, Sciences &Technology. Since 2024, he serves as the Vice-President of the Executive Council of the Institute.
